Scholars Central

Conference abstract

Augmentation of the immune response to a vaccine by innate immune modulators

Authors: Kei Amemiya

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The development of a protective vaccine may take years of evaluation of vaccine candidates that offer only limited protection in animal models. In many cases, the evaluation process goes through a whole- cell stage to subunit components that are more effective in providing protection. This was the case for the vaccine against Yersinia pestis, the etiological agent of plague. Although the presence of the disease has been noted for more than a thousand years, it was not until a little more than 100 years ago that the organism that caused this zoonotic disease was first identified. The whole-cell plague vaccine apparently only provided limited protection against a virulent challenge, while being more immunoreactive. Further understanding of the pathogenesis and identification of virulence factors of Y. pestis led to the development of a subunit vaccine that appears to offer a more robust and long-lasting protection in animal models of plague. The current vaccine candidate has gone through initial human clinical trials in both the United States and United Kingdom. Nevertheless, we still do not completely understand how protection is mediated by the vaccine candidate. As we learn more about the immune response in the host, and in particular the innate immune response that may alter the development of protective immunity, this provides us with additional parameters to evaluate and improve the efficacy of a vaccine candidate. We will present examples how immunomodulation of the innate immune system can augment the immune response to vaccine candidates, leading to an enhancement of their efficacy in their respective animal models.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vaccines & Vaccination
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Kei Amemiya”